Therapeutic Goods Legislation Amendment (2022 Measures No. 1) Regulations 2022

I, General the Honourable David Hurley AC DSC (Retd), Governor‑General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following regulations.

Dated 03 March 2022

David Hurley

Governor‑General

By His Excellency’s Command

Greg Hunt

Minister for Health and Aged Care

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Extemporaneously‑compounded medicinal cannabis products

Narcotic Drugs Regulation 2016

Therapeutic Goods Regulations 1990

Schedule 2—Minamata Convention on Mercury

Therapeutic Goods Regulations 1990

Schedule 3—Other amendments

Therapeutic Goods (Medical Devices) Regulations 2002

Therapeutic Goods Regulations 1990

1  Name

  This instrument is the Therapeutic Goods Legislation Amendment (2022 Measures No. 1) Regulations 2022.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under the following:

 (a) the Narcotic Drugs Act 1967;

 (b) the Therapeutic Goods Act 1989.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Extemporaneously‑compounded medicinal cannabis products

Narcotic Drugs Regulation 2016

1  After paragraph 4B(b)

Insert:

 (ba) the supply of a cannabis drug to a person for the purposes of that person supplying an extemporaneously-compounded medicinal cannabis product (within the meaning of the Therapeutic Goods Regulations 1990) in accordance with the Therapeutic Goods Act 1989;

2  After paragraph 11(c)

Insert:

 (ca) the supply is for the purposes of that person supplying an extemporaneously-compounded medicinal cannabis product (within the meaning of the Therapeutic Goods Regulations 1990) in accordance with the Therapeutic Goods Act 1989;

Therapeutic Goods Regulations 1990

3  In the appropriate position in Part 9

Insert:

Division 18—Application provisions relating to Schedule 1 to the Therapeutic Goods Legislation Amendment (2022 Measures No. 1) Regulations 2022

86  Extemporaneously‑compounded medicinal cannabis products

  The amendment of Schedule 5 to these Regulations made by Schedule 1 to the Therapeutic Goods Legislation Amendment (2022 Measures No. 1) Regulations 2022 does not apply in relation to a medicinal cannabis product that is extemporaneously compounded before 28 April 2022.

4  Schedule 5 (at the end of the cell at table item 6, column 2)

Add “or that are medicinal cannabis products”.

Schedule 2—Minamata Convention on Mercury

Therapeutic Goods Regulations 1990

1  Before subregulation 48(1)

Insert:

Definitions

2  Subregulation 48(1)

Insert:

eligible person, in relation to an initial decision specified in column 1 of an item of the following table, means a person specified in column 2 of the item.

3  Subregulation 48(1) (at the end of the definition of initial decision)

Add:

Note: See also subregulation (1AA) of this regulation.

4  After subregulation 48(1)

Insert:

 (1AA) Each of the following decisions of the Secretary under regulation 10JE or 10JF (about importing or exporting mercury) is an initial decision:

 (a) a decision to refuse to approve an application for approval;

 (b) a decision to revoke or vary an approval.

Delegation

5  Before subregulation 48(2)

Insert:

Requests for reconsideration of initial decisions

6  Subregulation 48(2)

Omit “A person whose interests are affected by”, substitute “An eligible person in relation to”.

7  Subregulation 48(2AA)

Repeal the subregulation.

8  Before subregulation 48(3)

Insert:

Reconsideration of initial decisions

9  Before subregulation 48(6)

Insert:

Notices about right to seek reconsideration of initial decisions

10  Subregulation 48(6)

Omit “whose interests are affected by” (first occurring), substitute “who is an eligible person in relation to”.

11  Subregulation 48(6)

Omit “a person whose interests are affected by the decision” (second occurring), substitute “the person”.

12  Before subregulation 48(7)

Insert:

Failure to comply with subregulations (5) and (6) does not affect decisions

13  Before subregulation 48(8)

Insert:

Applications for review of reviewable decisions

14  In the appropriate position in Part 9

Insert:

Division 19—Application provisions relating to Schedule 2 to the Therapeutic Goods Legislation Amendment (2022 Measures No. 1) Regulations 2022

87  Reconsideration of decisions

  The amendments of regulation 48 of these Regulations made by Schedule 2 to the Therapeutic Goods Legislation Amendment (2022 Measures No. 1) Regulations 2022 apply in relation to initial decisions made on or after the commencement of this regulation.

Schedule 3—Other amendments

Therapeutic Goods (Medical Devices) Regulations 2002

1  Subclause 13A.2(2) of Schedule 1 (table item 1, column headed “Information”, paragraph (c))

Omit “; and”.

2  Subclause 13A.2(2) of Schedule 1 (table item 1, column headed “Information”, paragraph (d))

Repeal the paragraph.

3  Dictionary (definition of unique device identifier)

Repeal the definition.

Therapeutic Goods Regulations 1990

4  Subregulation 12A(1)

Omit “the 9th Schedule to the Poisons Standard, as in force from time to time”, substitute “Schedule 9 or 10 to the Poisons Standard”.